Who are AB-106, digoxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DIGOXIN, Lanoxin, Rate-control therapy, Cinobufacini Injection, Intra-amniotic injection of DIGOXIN, Magnesium sulfate and then Digoxin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ab-106-digoxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AB-106, digoxin — Competitive Intelligence Brief

AB-106, digoxin (AB-106, digoxin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac glycoside. Area: Cardiovascular.

phase 1 Cardiac glycoside Sodium-potassium ATPase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AB-106, digoxin (AB-106, digoxin) — Nuvation Bio Inc.. Digoxin inhibits the sodium-potassium ATPase pump.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AB-106, digoxin TARGET	AB-106, digoxin	Nuvation Bio Inc.	phase 1	Cardiac glycoside	Sodium-potassium ATPase
DIGOXIN	DIGOXIN		marketed	Cardiac Glycoside [EPC]		1975-01-01
Lanoxin	digoxin	Generic (originally Burroughs Wellcome/GSK)	marketed	Cardiac Glycoside [EPC]	Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2	1954-01-01
Rate-control therapy	Rate-control therapy	Our Lady of the Lake Hospital	marketed	AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides)	AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)
Cinobufacini Injection	Cinobufacini Injection	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Natural product bufadienolide; cardiac glycoside analog	Na+/K+-ATPase; multiple apoptotic pathways
Intra-amniotic injection of DIGOXIN	Intra-amniotic injection of DIGOXIN	Meir Medical Center	phase 3	Cardiac glycoside	Na+/K+-ATPase
Magnesium sulfate and then Digoxin	Magnesium sulfate and then Digoxin	Sunnybrook Health Sciences Centre	phase 3	Electrolyte supplement and cardiac glycoside combination	Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cardiac glycoside class)

Advenchen Laboratories, LLC · 1 drug in this class
Meir Medical Center · 1 drug in this class
Nuvation Bio Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AB-106, digoxin — Competitive Intelligence Brief. https://druglandscape.com/ci/ab-106-digoxin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab